PSMA-TRACIr
We are developing a PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. Our PSMA-TRACIr is currently in IND-enabling studies.
Prostate cancer is a PSMA-TRACTr and PSMAxCD28-costimulation responsive tumor type. We are developing a PSMA-TRACIr to be used in combination with our PSMA-TRACTr JANX007.
We designed our PSMA-TRACIr product candidate as a double-masked TRACIr in which the PSMA-binding domain and the T cell-specific binding domain (CD28) is masked.
In preclinical studies, PSMA-TRACIr demonstrated cleavage dependent activity and enhanced the duration of the PSMA-TRACTr anti-tumor response.